PTI Proteostasis Therapeutics Inc.

1.2
-0.06  -5%
Previous Close 1.26
Open 1.25
Price To Book 0.54
Market Cap 61248738
Shares 51,040,615
Volume 1,451,589
Short Ratio
Av. Daily Volume 2,272,113

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 28-day data released December 11, 2017 - showed improvements in FEV1 of 5.2%. Phase 2 28-day data released December 11, 2017 - showed improvements in FEV1 of 5.2%.
PTI-428
Cystic fibrosis
Development to be discontinued due to lack of efficacy - March 25, 2019.
PTI-801 + Symdeko
Cystic fibrosis
Proceed to 28 day studies to confirm efficacy.
PTI-801 and PTI-808
Cystic fibrosis
Phase 1 28-day data due YE 2019. Data March 25, 2019 noted ppFEV1 of 5% in high dose.
PTI-428 + PTI-801 + PTI-808
Cystic fibrosis
Development to be discontinued due to lack of efficacy.
PTI-428 + Symdeko
Cystic fibrosis

Latest News

  1. Implied Volatility Surging for Proteostasis Therapeutics (PTI) Stock Options
  2. Proteostasis Plunges on Weak Data From Cystic Fibrosis Study
  3. Some Proteostasis Therapeutics (NASDAQ:PTI) Shareholders Have Taken A Painful 86% Share Price Drop
  4. The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs
  5. Why Vertex's Grip On This Huge Sales Opportunity Now Looks Unbreakable
  6. Proteostatis stock plunges on cystic fibrosis triple combo data
  7. Proteostasis Therapeutics's stock plunges to pace all decliners after results of CF treatment trial disappoint
  8. Proteostasis Therapeutics Announces Broad New Dataset from Proprietary Combination and Add-On CFTR Modulator Studies in Cystic Fibrosis Patients
  9. The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
  10. Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed
  11. Proteostasis Therapeutics Appoints David Arkowitz to Board of Directors
  12. Proteostasis Selected to Join European Consortium to Pioneer Personalized Medicine in Cystic Fibrosis
  13. Detailed Research: Economic Perspectives on Novartis AG, Proteostasis Therapeutics, Williams-Sonoma, Magna International, YRC Worldwide, and Delek Logistics Partners — What Drives Growth in Today's Competitive Landscape
  14. Proteostasis Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference
  15. Biotech Plays in the News You Should Know
  16. How Much Of Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Do Institutions Own?
  17. Biotech Stocks Set to Pop
  18. 4 Biotech Stocks Making Moves on Wednesday (2/6/19)
  19. Proteostasis Therapeutics Appoints Emmanuel Dulac and Kim Drapkin to Board of Directors
  20. These 4 Biotech Stocks Are Raising Eyebrows